WHO Announces Forthcoming Updates on the Systematic Screening for Tuberculosis
These changes will be included in the forthcoming guidance on systematic screening of TB to be released in early 2021.
- Community-wide systematic screening using a sensitive tool such as CXR followed by an accurate diagnostic test may be used in settings with TB prevalence even lower than 1% – based on evidence of public health benefit at such levels.
- Computer-aided detection CAD may be used as an alternative to human reader interpretation of plain digital CXR for screening and triage for TB. (15 years or more).
- Molecular rapid diagnostics (mWRDs) may be used for TB screening to improve the accuracy of symptom screening in high risk populations.
In people living with HIV:
- Screening with CXR improves the sensitivity of the WHO four-symptom screening (cough, fever, weight loss or night sweats) for detecting TB, including in people who attend HIV care services for ART.
- C-Reactive Protein may be used for TB screening over and above the WHO four-symptom screen in all people living with HIV in high TB-burden settings.
- mWRDs may be used to screen for TB in all people living with HIV as in other high-risk populations in high TB-burden settings.